FDAapproval83% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Merck.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Infectious Disease · Respiratory Syncytial Virus (RSV)
- Sub-indication
- General
Related signal: Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants